Research examines SGLT-2's effect on epicardial adipose tissue, suggesting benefits for cardiovascular diseases.
Epicardial adipose tissue (EAT) refers to a special type of coronary fat that is in direct contact with the myocardium and coronary arteries with no other tissue separating it.The results of many recent studies have shown that abnormal changes in the adipose tissue of the outer mucosa of the Heart play an important role in the development of various cardiovascular diseases, such as atrial fibrillation, coronary atherosclerosis, and electrical remodeling of the heart, as well as being closely associated with an increased risk of complications after surgery. However, SGLT - 2 inhibitors, a novel class of therapeutic agents, have demonstrated remarkable efficacy in ameliorating the pathological state of epicardial adipose tissue. This finding furnishes a novel mechanistic basis for the prophylaxis of cardiovascular diseases. This article will examine in detail the potential mechanism of action of the SGLT-2 inhibitor in improving the condition in the adipose tissue of the outer mucosa of the heart aiming to achieve the preventive effect against cardiovascular diseases.It seeks to provide new perspectives and evidence for the prevention and fight against cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Xu Sun (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: